pyrazines has been researched along with Adenocarcinoma in 60 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (1.67) | 18.7374 |
| 1990's | 10 (16.67) | 18.2507 |
| 2000's | 25 (41.67) | 29.6817 |
| 2010's | 22 (36.67) | 24.3611 |
| 2020's | 2 (3.33) | 2.80 |
| Authors | Studies |
|---|---|
| Kanda, Y; Miyazaki, T; Mori, Y; Ochiai, A; Ohata, H; Okamoto, K; Owa, T; Sakai, H; Shiokawa, D; Yokoi, A | 1 |
| Arthur, G; Bebb, DG; Bolyos, A; Bose, P; Goutam, S; Jette, NR; Lees-Miller, SP; Petersen, LF; Radhamani, S; Ye, R | 1 |
| Buckley, AM; Clarke, N; Davern, M; Dunne, MR; Foley, EK; Kennedy, BN; Kennedy, SA; Lysaght, J; MacCarthy, F; Morrissey, ME; Nolan, A; O'Sullivan, J; O'Toole, D; Ravi, N; Reynolds, JV | 1 |
| Buckley, AM; Cannon, A; Dunne, MR; Kennedy, BN; Kennedy, SA; Lynam-Lennon, N; Maher, SG; O'Sullivan, J; Reynolds, AL; Reynolds, JV | 1 |
| Eatock, MM; Gallagher, R; James, CR; Law, D; Millar, J; Morris, M; Napier, E; Purcell, C; Turkington, RC; Wilson, RH | 1 |
| Almeida, GM; Coelho, MA; Coelho, SC; Juzenas, P; Pereira, MC; Rocha, S; Sampaio, P; Silva, FS | 1 |
| Alpaugh, RK; Cheng, JD; Cohen, SJ; Cooper, H; Denlinger, CS; Engstrom, PF; Lewis, NL; Li, T; Meropol, NJ; Weiner, LM; Wright, JJ | 1 |
| Besanceney-Webler, C; Chen, EX; Cheng, J; Christos, P; Dilts, KT; Holloway, S; Keresztes, R; Lane, ME; Lin, J; Matulich, D; Ocean, AJ; Papetti, M; Schnoll-Sussman, F; Shah, MA; Sparano, JA; Ward, M; Wright, JJ; Xiang, J; Yantiss, RK | 1 |
| Ahn, MJ; Arpornwirat, W; Bazhenova, L; Chen, J; Chiappori, AA; Chow, LQ; de Lima, LG; Dechaphunkul, A; Eaton, K; Gadgeel, SM; Juergens, RA; Leighl, NB; Medley, S; Poondru, S; Rizvi, NA; Rudin, CM; Singh, M; Steinberg, J; Sunpaweravong, P | 1 |
| Cusack, JC; Houston, M; Liu, R; Ljungman, D; Palladino, MA; Sloss, CM; Wang, F; Xia, L | 1 |
| Avendaño, C; Cuesta, Ede L; González, JF; Manguan-García, C; Ortín, I; Perona, R | 1 |
| Anthoney, A; Bauer, J; Caponigro, F; Govaerts, AS; Lacombe, D; Marréaud, S; Milano, A; Twelves, C | 1 |
| Märten, A; Mehrle, S; Schmidt, J; Serba, S; von Lilienfeld-Toal, M; Zeiss, N | 1 |
| Albain, KS; Chansky, K; Crowley, J; Davies, AM; Gandara, DR; Gumerlock, PH; Lara, PN; Vogel, SJ | 1 |
| Cao, X; Garofalo, A; Grande, F; Louie, S; Neamati, N; Oshima, T; Yamada, R | 1 |
| Baritaki, S; Berenson, J; Bonavida, B; Palladino, M; Yeung, K | 1 |
| Bernard, SA; Calvo, BF; Caskey, LS; Chakravarthy, AB; Chan, E; Goldberg, RM; Ivanova, A; Kim, HJ; Myers, MO; O'Neil, BH; Raftery, L; Sanoff, HK; Tepper, JE; Wise, PE | 1 |
| Jones, DR; Liu, Y; Nagji, AS; Taylor, MD; Theodosakis, N | 1 |
| Capanu, M; Holen, KD; Ilson, DH; Kelsen, DP; Kemeny, MM; Kindler, HL; Power, DG; Shah, MA; Tang, L; Wright, JJ | 1 |
| Bugaj, JE; Gokhale, PC; Guleryuz, S; Manning, HC; Mantis, C; McKinley, ET; Wild, R; Zhao, P | 1 |
| Abduljabbar, A; Abubaker, J; Ahmed, M; Al-Dayel, F; Al-Kuraya, KS; Al-Sanea, N; Alhomoud, S; Ashari, LH; Bavi, P; Bu, R; Hussain, AR; Jehan, Z; Prabhakaran, S; Sultana, M; Uddin, S | 1 |
| Belani, CP; Davies, AM; Edelman, MJ; Gandara, DR; Gitlitz, B; Lara, PN; Longmate, J; Ramalingam, SS; Reckamp, K; Salgia, R; Villalona-Calero, M; Vokes, EE; Wright, JJ | 1 |
| Bronson, R; Feldser, DM; Jacks, T; Meylan, E; Oliver, TG; Winslow, MM; Xue, W | 1 |
| Arteaga, CL; Balko, JM; Buck, E; Fox, EM; González-Angulo, AM; Kuba, MG; Liu, S; Manning, HC; Miller, TW; Mills, GB; Sánchez, V; Shyr, Y; Smith, RA; Ye, F | 1 |
| Della Donna, L; Lagadec, C; Pajonk, F | 1 |
| Besse, B; Ducourtieux, M; Khayat, D; Lafontaine, C; Lumbroso, J; Mathiot, C; Pignon, JP; Planchard, D; Soria, JC; Taillade, L; Veillard, AS | 1 |
| Arastu-Kapur, S; Bennett, MK; Bergsagel, PL; Demo, S; Deu, E; Keats, J; Kirk, CJ; Suzuki, E | 1 |
| Pan, XJ; Xiao, W; Yang, ZH; Zheng, CY; Zhou, SY; Zhu, MX | 1 |
| Gartel, AL; Wang, M | 1 |
| Bao, Y; Burks, SG; Gillenwater, HH; Jones, DR; Kozower, BD; Moskaluk, CA; Olazagasti, J; Petroni, GR; Philips, J; Rehm, PK | 1 |
| Chen, LT; Chen, SH; Chen, TJ; Hsing, CH; Huang, HY; Lee, HH; Lee, SW; Li, CF; Lin, CY; Lin, LC; Pan, HY; Sheu, MJ; Shiue, YL; Tian, YF | 1 |
| Bold, RJ; Fahy, BN; Schlieman, MG; Virudachalam, S | 1 |
| Adachi, M; Hinoda, Y; Imai, K; Kawamura, R; Minami, T; Zhang, Y; Zhao, X | 1 |
| Denlinger, CE; Jones, DR; Keller, MD; Rundall, BK | 1 |
| Callery, MP; Canete, JJ; Chandler, NM | 1 |
| Alberts, SR; Block, M; Burch, P; Foster, N; Jatoi, A; Kugler, J; Morton, R; Nguyen, PL | 1 |
| Ebert, B; Lampen, A; Seidel, A | 1 |
| Alberts, SR; Fitch, TR; Foster, NR; Gill, S; Kim, GP; Kugler, J; Morton, RF; Schaefer, P; Steen, P; Wiesenfeld, M | 1 |
| Alexandre, J | 1 |
| Laurie, SA; Licitra, L | 1 |
| Chao, TH; Cusack, JC; Liu, R; Neuteboom, ST; Niu, W; Palladino, MA; Palombella, VJ; Pien, C; Xia, L | 1 |
| Agus, D; Dreicer, R; Petrylak, D; Roth, B; Webb, I | 1 |
| Barton, J; Gould, B; Greco, FA; Hainsworth, JD; Meluch, AA; Meng, C; Simons, L; Spigel, DR | 1 |
| Gao, SL; Shen, HW; Tang, ZY; Wu, YL | 1 |
| Badve, S; Bergan, R; Brown, JA; Engel, RH; Gradishar, WJ; O'Regan, RM; Rademaker, A; Von Roenn, JH | 1 |
| Brooks, AD; Elliott, PJ; Murphy, WJ; Sayers, TJ; Shanker, A; Smyth, MJ; Takeda, K; Tristan, CA; Wine, JW; Yagita, H | 1 |
| AbdulJabbar, A; Ahmed, M; Al-Dayel, F; Al-Kuraya, KS; Al-Sanea, N; Alhomoud, S; Ashari, LH; Bavi, P; El-Sayed, R; Hussain, AR; Uddin, S | 1 |
| Cameron, IL; Pool, TB; Smith, NK; Sparks, RL | 1 |
| Braguer, D; Briand, C; Carles, G; Garcia, P | 1 |
| Katiwalla, M; Kelloff, GJ; Rao, CV; Reddy, BS; Rivenson, A | 1 |
| Hirahara, N; Minari, Y; Nio, Y; Ohmori, H; Sasaki, S; Takamura, M; Tamura, K | 1 |
| Abbruzzese, JL; Ajani, J; Diaz-Canton, E; Grove, W; Meyers, C; Patt, Y; Pazdur, R | 1 |
| Furukawa, F; Ikezaki, S; Kasahara, K; Lee, IS; Nishikawa, A; Takahashi, M; Tanakamura, Z | 1 |
| Clayton, M; Halbherr, T; Myers, CB; O'Dwyer, PJ; Yao, Ks | 1 |
| Fujita, M; Higashino, K; Tsuchida, T | 1 |
| Chen, SX; Wang, LX; Xing, LL | 1 |
| Adams, J; Ara, G; Herbst, R; Palombella, VJ; Teicher, BA | 1 |
| Vandré, DD; Weitzel, DH | 1 |
| Bold, RJ; McConkey, DJ; Virudachalam, S | 1 |
| Bai, H; Chen, F; Hu, G; Luo, X; Wei, H; Zhu, M | 1 |
1 review(s) available for pyrazines and Adenocarcinoma
| Article | Year |
|---|---|
Systemic therapy in the palliative management of advanced salivary gland cancers.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Boronic Acids; Bortezomib; Carcinoma, Adenoid Cystic; Carcinoma, Mucoepidermoid; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Humans; Lapatinib; Neoplasm Metastasis; Neoplasm Recurrence, Local; Palliative Care; Pyrazines; Quinazolines; Receptor, ErbB-2; Receptors, Androgen; Salivary Ducts; Salivary Gland Neoplasms; Trastuzumab | 2006 |
17 trial(s) available for pyrazines and Adenocarcinoma
| Article | Year |
|---|---|
A phase I trial of bortezomib in combination with epirubicin, carboplatin and capecitabine (ECarboX) in advanced oesophagogastric adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carboplatin; Deoxycytidine; Epirubicin; Female; Gastrointestinal Neoplasms; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Proteasome Inhibitors; Pyrazines | 2014 |
A phase II trial of the proteasome inhibitor bortezomib in patients with advanced biliary tract cancers.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Boronic Acids; Bortezomib; Cholangiocarcinoma; Disease Progression; Female; Follow-Up Studies; Gallbladder Neoplasms; Humans; Male; Middle Aged; Proteasome Inhibitors; Pyrazines; Survival Rate; Time Factors; Treatment Outcome | 2014 |
Phase II trial of bortezomib alone or in combination with irinotecan in patients with adenocarcinoma of the gastroesophageal junction or stomach.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Camptothecin; Esophageal Neoplasms; Female; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Male; Middle Aged; Oligonucleotide Array Sequence Analysis; Proteasome Inhibitors; Pyrazines; Stomach Neoplasms | 2014 |
Phase 2 Study of Erlotinib in Combination With Linsitinib (OSI-906) or Placebo in Chemotherapy-Naive Patients With Non-Small-Cell Lung Cancer and Activating Epidermal Growth Factor Receptor Mutations.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Double-Blind Method; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Imidazoles; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Pyrazines; Survival Rate | 2017 |
An EORTC phase I study of Bortezomib in combination with oxaliplatin, leucovorin and 5-fluorouracil in patients with advanced colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Colorectal Neoplasms; Disease-Free Survival; DNA Repair; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Polymorphism, Genetic; Pyrazines; Survival Rate | 2009 |
Bortezomib plus gemcitabine/carboplatin as first-line treatment of advanced non-small cell lung cancer: a phase II Southwest Oncology Group Study (S0339).
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cohort Studies; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Prognosis; Pyrazines; Survival Rate; Treatment Outcome | 2009 |
A phase I study of bortezomib in combination with standard 5-fluorouracil and external-beam radiation therapy for the treatment of locally advanced or metastatic rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Boronic Acids; Bortezomib; Disease Progression; Drug Therapy, Combination; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; NF-kappa B; Pyrazines; Rectal Neoplasms | 2010 |
A multicenter, phase II study of bortezomib (PS-341) in patients with unresectable or metastatic gastric and gastroesophageal junction adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Esophagogastric Junction; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; NF-kappa B; Protease Inhibitors; Pyrazines; Stomach Neoplasms; Treatment Outcome | 2011 |
Bortezomib for patients with advanced-stage bronchioloalveolar carcinoma: a California Cancer Consortium Phase II study (NCI 7003).
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; California; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Pyrazines; Survival Rate; Treatment Outcome | 2011 |
Phase 2 study of frontline bortezomib in patients with advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Female; Follow-Up Studies; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplastic Cells, Circulating; Prognosis; Pyrazines; Survival Rate | 2012 |
Phase I trial of induction histone deacetylase and proteasome inhibition followed by surgery in non-small-cell lung cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Boronic Acids; Bortezomib; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Combined Modality Therapy; Female; Follow-Up Studies; Gene Expression Profiling; Histone Deacetylases; Humans; Hydroxamic Acids; Immunoenzyme Techniques; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Oligonucleotide Array Sequence Analysis; Prognosis; Proteasome Endopeptidase Complex; Pyrazines; Vorinostat | 2012 |
PS-341 and gemcitabine in patients with metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group (NCCTG) randomized phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Infusions, Intravenous; Injections, Intravenous; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Pyrazines; Survival Analysis; Treatment Outcome | 2005 |
Phase I/II study of bortezomib plus docetaxel in patients with advanced androgen-independent prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgens; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Docetaxel; Dose-Response Relationship, Drug; Humans; Interleukin-6; Male; Middle Aged; Neoplasms, Hormone-Dependent; Prostate-Specific Antigen; Prostatic Neoplasms; Pyrazines; Taxoids | 2007 |
Weekly docetaxel and bortezomib as first-line treatment for patients with hormone-refractory prostate cancer: a Minnie Pearl Cancer Research Network phase II trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgens; Antineoplastic Agents; Boronic Acids; Bortezomib; Docetaxel; Drug Administration Schedule; Humans; Male; Middle Aged; Prostatic Neoplasms; Pyrazines; Taxoids; Treatment Outcome | 2007 |
A phase II study of single agent bortezomib in patients with metastatic breast cancer: a single institution experience.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Boronic Acids; Bortezomib; Breast Neoplasms; Female; Humans; Middle Aged; Protease Inhibitors; Pyrazines; Treatment Outcome | 2007 |
Phase II trial of intravenous CI-980 (NSC 370147) in patients with metastatic colorectal carcinoma. Model for prospective evaluation of neurotoxicity.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carbamates; Central Nervous System Diseases; Colorectal Neoplasms; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Prospective Studies; Pyrazines; Pyridines | 1997 |
[Effects of tetramethylpyrazine on platelet functions of advanced cases of lung carcinoma].
Topics: 6-Ketoprostaglandin F1 alpha; Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Female; Humans; Lung Neoplasms; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Pyrazines; Thromboxane B2 | 1997 |
42 other study(ies) available for pyrazines and Adenocarcinoma
| Article | Year |
|---|---|
NF-κB suppression synergizes with E7386, an inhibitor of CBP/β-catenin interaction, to block proliferation of patient-derived colon cancer spheroids.
Topics: Adenocarcinoma; beta Catenin; Cell Cycle Checkpoints; Cell Proliferation; Colonic Neoplasms; CREB-Binding Protein; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; NF-kappa B; Phenylenediamines; Primary Cell Culture; Pyrazines; Spheroids, Cellular; Triazines; Wnt Signaling Pathway | 2022 |
Combined poly-ADP ribose polymerase and ataxia-telangiectasia mutated/Rad3-related inhibition targets ataxia-telangiectasia mutated-deficient lung cancer cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Ataxia Telangiectasia Mutated Proteins; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Clustered Regularly Interspaced Short Palindromic Repeats; Gene Deletion; Histones; Humans; Lung Neoplasms; Mutation; Nitroso Compounds; Phosphorylation; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Pyrazines; Pyrimidines; RNA, Messenger; Sulfones; Tumor Suppressor Protein p53 | 2019 |
Real-time metabolic profiling of oesophageal tumours reveals an altered metabolic phenotype to different oxygen tensions and to treatment with Pyrazinib.
Topics: Adenocarcinoma; Biopsy; Cell Line, Tumor; Cell Proliferation; Cell Survival; Esophageal Neoplasms; Glycolysis; Humans; Jurkat Cells; Metabolomics; Oxidative Phosphorylation; Oxygen Consumption; Phenotype; Pyrazines | 2020 |
Pyrazinib (P3), [(E)-2-(2-Pyrazin-2-yl-vinyl)-phenol], a small molecule pyrazine compound enhances radiosensitivity in oesophageal adenocarcinoma.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Esophageal Neoplasms; Humans; Neoadjuvant Therapy; Phenols; Pyrazines; Radiation Tolerance; Radiation-Sensitizing Agents; Small Molecule Libraries; Zebrafish | 2019 |
Gold nanoparticle delivery-enhanced proteasome inhibitor effect in adenocarcinoma cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Drug Delivery Systems; Drug Synergism; Epithelial Cells; Gold; Humans; Nanoparticles; Pancreatic Ducts; Pancreatic Neoplasms; Polyethylene Glycols; Proteasome Inhibitors; Pyrazines; Tumor Cells, Cultured | 2013 |
Proteasome inhibition activates epidermal growth factor receptor (EGFR) and EGFR-independent mitogenic kinase signaling pathways in pancreatic cancer cells.
Topics: Adenocarcinoma; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bevacizumab; Blotting, Western; Boronic Acids; Bortezomib; Cell Line, Tumor; Cetuximab; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lactones; Mice; Mice, Nude; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Pyrroles; Quinazolines; Signal Transduction; Xenograft Model Antitumor Assays | 2008 |
Pyrazino[1,2-b]isoquinolines: synthesis and study of their cytostatic and cytotoxic properties.
Topics: Adenocarcinoma; Apoptosis; Cell Cycle; Cell Division; Cell Line, Tumor; Cytostatic Agents; DNA Damage; G1 Phase; G2 Phase; HT29 Cells; Humans; Inhibitory Concentration 50; Isoquinolines; JNK Mitogen-Activated Protein Kinases; Lung Neoplasms; p38 Mitogen-Activated Protein Kinases; Proto-Oncogene Proteins c-akt; Pyrazines; S Phase; Structure-Activity Relationship | 2008 |
Bortezomib is ineffective in an orthotopic mouse model of pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Immunohistochemistry; Male; Mice; Mice, Inbred C57BL; Neovascularization, Pathologic; Pancreatic Neoplasms; Pyrazines; RGS Proteins; Vascular Endothelial Growth Factor A | 2008 |
Combination effects of SC144 and cytotoxic anticancer agents.
Topics: Adenocarcinoma; Administration, Oral; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Colorectal Neoplasms; Cytotoxins; Drug Screening Assays, Antitumor; Drug Synergism; Female; Humans; Inhibitory Concentration 50; Injections, Intraperitoneal; Mice; Mice, Nude; Organoplatinum Compounds; Paclitaxel; Pyrazines; Quinoxalines; Xenograft Model Antitumor Assays | 2009 |
Pivotal roles of snail inhibition and RKIP induction by the proteasome inhibitor NPI-0052 in tumor cell chemoimmunosensitization.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cisplatin; Humans; Lactones; Leupeptins; Male; Melanoma; Membrane Potential, Mitochondrial; NF-kappa B; Phosphatidylethanolamine Binding Protein; Prostatic Neoplasms; Proteasome Inhibitors; Proto-Oncogene Proteins c-raf; Pyrazines; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Snail Family Transcription Factors; TNF-Related Apoptosis-Inducing Ligand; Transcription Factors; Transfection; Tumor Cells, Cultured | 2009 |
Combined proteasome and histone deacetylase inhibition attenuates epithelial-mesenchymal transition through E-cadherin in esophageal cancer cells.
Topics: Adenocarcinoma; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cadherins; Carcinoma, Squamous Cell; Cell Death; Cell Line, Tumor; Cell Movement; Epithelial Cells; Esophageal Neoplasms; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxamic Acids; Mesoderm; Neoplasm Invasiveness; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; RNA, Messenger; Spheroids, Cellular; Time Factors; Transfection; Transforming Growth Factor beta; Tumor Necrosis Factor-alpha; Up-Regulation; Vorinostat | 2010 |
18FDG-PET predicts pharmacodynamic response to OSI-906, a dual IGF-1R/IR inhibitor, in preclinical mouse models of lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Cell Line, Tumor; Drug Evaluation, Preclinical; Female; Fluorodeoxyglucose F18; Humans; Imidazoles; Lung Neoplasms; Mice; Mice, Nude; Positron-Emission Tomography; Prognosis; Protein Kinase Inhibitors; Pyrazines; Receptor, IGF Type 1; Receptor, Insulin; Xenograft Model Antitumor Assays | 2011 |
Bortezomib stabilizes mitotic cyclins and prevents cell cycle progression via inhibition of UBE2C in colorectal carcinoma.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Biomarkers, Tumor; Boronic Acids; Bortezomib; Cell Cycle; Colorectal Neoplasms; Cyclins; Gene Dosage; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Mice; Mice, Nude; Prognosis; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Small Interfering; Tissue Array Analysis; Ubiquitin-Conjugating Enzymes; Xenograft Model Antitumor Assays | 2011 |
Response and resistance to NF-κB inhibitors in mouse models of lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Resistance, Neoplasm; Lung Neoplasms; Mice; Mice, 129 Strain; NF-kappa B; Nitriles; Pyrazines; Signal Transduction; Sulfones; Survival Rate; Transcription Factor RelA | 2011 |
A kinome-wide screen identifies the insulin/IGF-I receptor pathway as a mechanism of escape from hormone dependence in breast cancer.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Line, Tumor; Disease-Free Survival; Estradiol; Estrogen Receptor Modulators; Estrogens; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Insulin; Insulin-Like Growth Factor I; Mice; Mice, Nude; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Protein-Tyrosine Kinases; Pyrazines; Random Allocation; Receptor, IGF Type 1; Receptor, Insulin; Receptors, Estrogen; RNA Interference; Signal Transduction; Tamoxifen; Xenograft Model Antitumor Assays | 2011 |
Radioresistance of prostate cancer cells with low proteasome activity.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Disease Models, Animal; Drug Resistance, Neoplasm; Humans; Male; Mice; Mice, Nude; Phenotype; Prostatic Neoplasms; Proteasome Endopeptidase Complex; Pyrazines; Radiation Tolerance; Radiotherapy; Treatment Failure | 2012 |
Molecular mechanisms of bortezomib resistant adenocarcinoma cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Blotting, Western; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Resistance, Neoplasm; Enzyme-Linked Immunosorbent Assay; Humans; Pyrazines | 2011 |
Inhibition of cyclooxygenase-2 by tetramethylpyrazine and its effects on A549 cell invasion and metastasis.
Topics: Adenocarcinoma; Animals; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclooxygenase 2 Inhibitors; Dinoprostone; Female; Humans; Immunoglobulin G; Lung Neoplasms; Matrix Metalloproteinase 2; Melphalan; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Pyrazines; Xenograft Model Antitumor Assays | 2012 |
Combination with bortezomib enhances the antitumor effects of nanoparticle-encapsulated thiostrepton.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Breast Neoplasms; Cell Line, Tumor; Drug Synergism; Female; Humans; Male; Mice; Mice, Nude; Nanocapsules; Proteasome Endopeptidase Complex; Pyrazines; Random Allocation; Thiostrepton; Tissue Distribution; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
SKP2 overexpression is associated with a poor prognosis of rectal cancer treated with chemoradiotherapy and represents a therapeutic target with high potential.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Blotting, Western; Boronic Acids; Bortezomib; Cell Proliferation; Chemoradiotherapy; Female; Fluorouracil; Follow-Up Studies; Humans; Immunoenzyme Techniques; Male; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Prognosis; Pyrazines; Rectal Neoplasms; Retrospective Studies; S-Phase Kinase-Associated Proteins; Survival Rate; Tumor Cells, Cultured | 2013 |
Schedule-dependent molecular effects of the proteasome inhibitor bortezomib and gemcitabine in pancreatic cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Biomarkers, Tumor; Boronic Acids; Bortezomib; Cell Cycle Proteins; Deoxycytidine; Drug Administration Schedule; Drug Synergism; Gemcitabine; Humans; Pancreatic Neoplasms; Protease Inhibitors; Pyrazines; Tumor Cells, Cultured | 2003 |
Synergistic effect of histone deacetylase inhibitors FK228 and m-carboxycinnamic acid bis-hydroxamide with proteasome inhibitors PSI and PS-341 against gastrointestinal adenocarcinoma cells.
Topics: Adenocarcinoma; Annexin A5; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Caspase 3; Caspases; Cell Line, Tumor; Cinnamates; Colonic Neoplasms; Depsipeptides; DNA Fragmentation; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Inhibitors; Free Radicals; Gastrointestinal Neoplasms; Histones; Humans; Microscopy, Confocal; Oligopeptides; Oxygen; Phosphorylation; Proteasome Inhibitors; Pyrazines; Reactive Oxygen Species; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Time Factors | 2004 |
Proteasome inhibition sensitizes non-small-cell lung cancer to gemcitabine-induced apoptosis.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Deoxycytidine; Drug Screening Assays, Antitumor; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mice; Mice, Nude; Neoplasm Proteins; NF-kappa B; Proteasome Inhibitors; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; Transcription Factor RelA; Transcription, Genetic; Tumor Stem Cell Assay; Xenograft Model Antitumor Assays | 2004 |
Caspase-3 drives apoptosis in pancreatic cancer cells after treatment with gemcitabine.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Apoptosis; Boronic Acids; Bortezomib; Caspase 3; Caspases; Cell Line; Deoxycytidine; Enzyme Activation; Gemcitabine; Humans; Immunoblotting; Pancreatic Neoplasms; Protease Inhibitors; Pyrazines; Ribonucleotide Reductases; Tumor Cells, Cultured | 2004 |
Is bortezomib, a proteasome inhibitor, effective in treating cancer-associated weight loss? Preliminary results from the North Central Cancer Treatment Group.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Boronic Acids; Bortezomib; Clinical Trials as Topic; Female; Gastrointestinal Agents; Humans; Male; Middle Aged; Octreotide; Pancreatic Neoplasms; Protease Inhibitors; Pyrazines; Statistics, Nonparametric; Treatment Outcome; Weight Loss | 2005 |
Identification of BCRP as transporter of benzo[a]pyrene conjugates metabolically formed in Caco-2 cells and its induction by Ah-receptor agonists.
Topics: Adenocarcinoma; Anticarcinogenic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzo(a)pyrene; Biological Transport; Cell Line, Tumor; Colonic Neoplasms; Enzyme Inhibitors; Flavonoids; Gene Expression Regulation, Neoplastic; Humans; Kinetics; Neoplasm Proteins; Polychlorinated Dibenzodioxins; Pyrazines; Receptors, Aryl Hydrocarbon; Reserpine; RNA, Messenger; Thiones; Thiophenes | 2005 |
[Proteasome inhibitors].
Topics: Adenocarcinoma; Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dexamethasone; Docetaxel; Drug Therapy, Combination; Female; Graft vs Host Reaction; Humans; Kidney Neoplasms; Lung Neoplasms; Lymphoma, Mantle-Cell; Male; Mice; Multiple Myeloma; Prostatic Neoplasms; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Taxoids; Time Factors; Treatment Outcome; Tumor Cells, Cultured | 2005 |
NPI-0052 enhances tumoricidal response to conventional cancer therapy in a colon cancer model.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Colonic Neoplasms; Drug Administration Routes; Drug Synergism; Female; Humans; Lactones; Mice; Mice, Nude; NF-kappa B; Proteasome Endopeptidase Complex; Pyrazines; Pyrroles; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha; Xenograft Model Antitumor Assays | 2006 |
Effects of the proteasome inhibitor bortezomib on gene expression profiles of pancreatic cancer cells.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; NF-kappa B; Oligonucleotide Array Sequence Analysis; Pancreatic Neoplasms; Protease Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Tumor Suppressor Protein p53 | 2008 |
Treating metastatic solid tumors with bortezomib and a tumor necrosis factor-related apoptosis-inducing ligand receptor agonist antibody.
Topics: Adenocarcinoma; Animals; Antibodies, Monoclonal; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Caspase 3; Caspase 8; Cell Line, Tumor; Cell Survival; Female; Flow Cytometry; Humans; Immunoblotting; Kidney Neoplasms; Lung Neoplasms; Mammary Neoplasms, Animal; Mice; Mice, Inbred BALB C; Mitochondrial Membranes; Protease Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Receptors, TNF-Related Apoptosis-Inducing Ligand; Signal Transduction; TNF-Related Apoptosis-Inducing Ligand | 2008 |
Bortezomib (Velcade) induces p27Kip1 expression through S-phase kinase protein 2 degradation in colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Cell Proliferation; Colorectal Neoplasms; Cyclin-Dependent Kinase Inhibitor p27; Female; Humans; Male; Mice; Mice, Nude; Middle Aged; Protease Inhibitors; Proteasome Inhibitors; Protein Processing, Post-Translational; Pyrazines; S-Phase Kinase-Associated Proteins; Tissue Array Analysis; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2008 |
Effects of amiloride on tumor growth and intracellular element content of tumor cells in vivo.
Topics: Adenocarcinoma; Amiloride; Animals; Body Weight; Cell Cycle; Cell Division; Cell Transformation, Neoplastic; Liver Neoplasms, Experimental; Male; Mice; Pyrazines; Sodium | 1983 |
[Effect of the association of antimitotic agents on cell lines of human adenocarcinoma].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carbamates; Colonic Neoplasms; Docetaxel; Humans; Paclitaxel; Pyrazines; Pyridines; Skin Neoplasms; Taxoids; Tumor Cells, Cultured; Urinary Bladder Neoplasms; Vinblastine; Vinorelbine | 1994 |
Chemopreventive effect of oltipraz during different stages of experimental colon carcinogenesis induced by azoxymethane in male F344 rats.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Azoxymethane; Colonic Neoplasms; Drug Administration Schedule; Drug Screening Assays, Antitumor; Male; Pyrazines; Rats; Rats, Inbred F344; Thiones; Thiophenes | 1993 |
A quinolinone derivative, vesnarinone (OPC-8212), significantly inhibits the in vitro and in vivo growth of human pancreatic cancer cell lines.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cell Division; Cell Survival; Collagen; Drug Combinations; Extracellular Matrix; Humans; Laminin; Mice; Mice, Nude; Neoplasm Invasiveness; Pancreatic Neoplasms; Proteoglycans; Pyrazines; Quinolines; Transplantation, Heterologous; Tumor Cells, Cultured | 1997 |
Chemopreventive activity of oltipraz against induction of glandular stomach carcinogenesis in rats by N-methyl-N'-nitro-N-nitrosoguanidine.
Topics: Adenocarcinoma; Animals; Anticarcinogenic Agents; Hyperplasia; Male; Methylnitronitrosoguanidine; Pylorus; Pyrazines; Rats; Rats, Wistar; Stomach Neoplasms; Thiones; Thiophenes | 1998 |
Cellular kinetics of induction by oltipraz and its keto derivative of detoxication enzymes in human colon adenocarcinoma cells.
Topics: Adenocarcinoma; Anticarcinogenic Agents; Cell Cycle; Cell Survival; Colonic Neoplasms; Gene Expression Regulation, Neoplastic; Glutathione Transferase; Humans; Inactivation, Metabolic; Kinetics; NAD(P)H Dehydrogenase (Quinone); Pyrazines; RNA, Messenger; Thiones; Thiophenes; Transcription, Genetic; Tumor Cells, Cultured | 1997 |
Effect of vesnarinone in combination with anti-cancer drugs on lung cancer cell lines.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cell Division; Cisplatin; Coloring Agents; Deoxycytidine; DNA Fragmentation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Etoposide; Flow Cytometry; Gemcitabine; Humans; Lung Neoplasms; Pyrazines; Quinolines; Tetrazolium Salts; Thiazoles; Tumor Cells, Cultured | 1999 |
The proteasome inhibitor PS-341 in cancer therapy.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Breast Neoplasms; Cisplatin; Cyclophosphamide; Dipeptides; Drug Synergism; Humans; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Protease Inhibitors; Pyrazines; Radiation-Sensitizing Agents; Tumor Cells, Cultured; Ubiquitins | 1999 |
Differential spindle assembly checkpoint response in human lung adenocarcinoma cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Carbamates; Fluorescent Antibody Technique, Indirect; Giant Cells; Humans; Lung Neoplasms; Microtubules; Mitosis; Pyrazines; Pyridines; Spindle Apparatus; Tumor Cells, Cultured | 2000 |
Chemosensitization of pancreatic cancer by inhibition of the 26S proteasome.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Deoxycytidine; Gemcitabine; Humans; Mice; Mice, Nude; Pancreatic Neoplasms; Peptide Hydrolases; Poly(ADP-ribose) Polymerases; Protease Inhibitors; Proteasome Endopeptidase Complex; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Transfection; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2001 |
[Studies on apoptosis of human lung adenocarcinoma cells induced by oltipraz].
Topics: Adenocarcinoma; Anticarcinogenic Agents; Apoptosis; Dose-Response Relationship, Drug; Humans; Lung Neoplasms; Mitosis; Pyrazines; Thiones; Thiophenes; Tumor Cells, Cultured | 1999 |